GET DAILY SIGNALSVerastem Oncology (VSTM) Reports Q3 2026 Results With Revenue Growth and Pipeline Progress
Key Takeaways
- Verastem Oncology reported third quarter 2026 net product revenue of $24.0 million, up from $11.2 million in the prior-year quarter, but slightly below analyst expectations.
- GAAP net loss was $74.7 million, or $0.74 per share, compared with $98.5 million, or $1.35 per share, a year earlier.
- Non-GAAP adjusted net loss was $72.8 million, or $0.72 per share, wider than the roughly $0.44 loss-per-share consensus estimate.
- Research and development spending climbed 137% year over year to $68.8 million, driven by the VS-7375 pipeline and pivotal trial preparations.
- The company ended the quarter with $172.8 million in cash and investments, or about $422.8 million on a pro forma basis after an October offering.
Earnings Context and Why It Matters
Verastem Oncology is a commercial-stage biopharmaceutical company focused on cancers driven by the RAS/MAPK signaling pathway. Its third quarter 2026 report matters because it measures two things at once: the continued commercial ramp of AVMAPKI FAKZYNJA CO-PACK, its first approved product for low-grade serous ovarian cancer (LGSOC), and the escalating investment in VS-7375, an oral KRAS G12D inhibitor the company views as a potential best-in-class asset. Investors are watching whether commercial revenue growth can keep pace with rising research costs, and whether clinical data readouts can justify a more aggressive pipeline build-out. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
For the third quarter ended September 30, 2026, Verastem Oncology reported net product revenue of $24.0 million, up from $11.2 million in the same period a year earlier. The figure fell short of consensus estimates, which ranged from roughly $26 million to $26.8 million, as management described a more gradual sales ramp tied to the episodic nature of treatment persistence in a rare disease.
On a GAAP basis, the net loss was $74.7 million, or $0.74 per share, compared with a net loss of $98.5 million, or $1.35 per share, in the prior-year quarter. Non-GAAP adjusted net loss was $72.8 million, or $0.72 per share, versus $39.1 million, or $0.53 per share, a year ago. Both measures missed analyst expectations for a narrower loss.
Operating expenses totaled $99.2 million. Research and development costs rose 137% to $68.8 million, reflecting expanded clinical activity for VS-7375, while selling, general and administrative expenses increased 26% to $26.5 million. Management noted that VS-7375 delivered a 41% confirmed objective response rate (ORR) in previously treated pancreatic ductal adenocarcinoma (PDAC), including a 50% confirmed ORR in second-line patients.
Market Reaction and Investor Sentiment
Reaction to the report centered on the revenue and bottom-line misses, with shares having added significantly year to date before the announcement. Sentiment remains divided: bulls point to the roughly doubled year-over-year product revenue, the strong refill dynamics supporting the CO-PACK launch, and the emerging VS-7375 clinical data, while bears focus on the steep rise in operating expenses and the wider-than-expected loss. The company's move to strengthen its balance sheet with a $250 million October offering signals both confidence in the pipeline and a willingness to fund costly pivotal development. From what I see, the balance sheet position gives the company meaningful runway to execute on its plans.
Forward Outlook and Key Factors to Monitor
Verastem's near-term narrative will be shaped by execution on two fronts. On the commercial side, investors should watch whether the CO-PACK revenue ramp accelerates as prescribers gain experience and as the new AVMAPKI tablet and blister pack formulation — which the FDA accepted for priority review with a decision expected by February 2027 — supports adherence and refills. I’m watching this closely as the formulation update could help with patient persistence.
On the clinical side, the focus shifts to VS-7375. Following alignment with the FDA, the company plans to open its Phase 3 TARGET-D 301 trial in first-line KRAS G12D-driven metastatic pancreatic cancer by the end of 2026, with additional regulatory engagement planned on Phase 3 designs in colorectal and lung cancers.
Cost trends will remain a key monitor. The 137% increase in R&D spending reflects the burden of advancing multiple pivotal programs, and sustained investment could pressure the bottom line even as revenue grows. With pro forma cash of roughly $422.8 million and a stated runway into the first half of 2028, the company has flexibility, but investors will weigh the pace of spending against the cadence of data readouts and regulatory milestones.
Exploring Biotech Opportunities with AI Tools
In my view, tools like Tickeron’s AI Screener can help investors quickly compare names like Verastem against peers by filtering on fundamentals, technical patterns, and sector trends. I’ve found it useful for spotting similar opportunities in oncology without spending hours on manual screens, especially when tracking multiple pipeline stories at once.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for VSTM turns positive, indicating new upward trend
VSTM saw its Momentum Indicator move above the 0 level on October 15, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 83 similar instances where the indicator turned positive. In 75 of the 83 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
VSTM moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where VSTM advanced for three days, in 205 of 250 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The Aroon Indicator entered an Uptrend today. In 162 of 188 cases where VSTM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 56 cases where VSTM's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 79%.
The Moving Average Convergence Divergence Histogram (MACD) for VSTM turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 35 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VSTM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
VSTM broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. VSTM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.846) is normal, around the industry mean (2.904). P/E Ratio (-4.037) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (7.446) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VSTM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company that discovers and develops drugs
Industry Biotechnology
Advertisement